3. Locteron (OctoPlus /Biolex; phase-2), a long-acting interferon made in transgenic plants: #msg-24304055.
4. Various oral agents in phase-1 or phase-2 trials that use an established MoA. These include TMC435350 (Medivir/JNJ, entering phase-2): #msg-24754963; R7128 (VRUS/Roche; phase-1b): #msg-25785397; ITMN-191/R7227 (ITMN/Roche; phase 1b):#msg-25786271; and R1626 (Roche; phase-2): #msg-24230355.
5. The “other” interferons: Albuferon (NVS/HGSI; phase-3): #msg-26199740; and ifn-Lambda (ZGEN; phase-1): #msg-16610804. (I’m excluding MAXY’s Maxy-alpha, which has been on life support since Roche dropped the program: #msg-24801678.)
6. Miscellaneous very-early-stage compounds that use an established MoA; e.g. IDX184 from IDIX: #msg-25802238, #msg-25836105.
7. GS9190 (GILD; phase-1), which has caused QT-prolongation: #msg-24268443.
8. Miscellaneous early-stage compounds that use novel MoA’s; e.g. Sirna-034, now owned by MRK: #msg-12665661.
9. HCV-796 (VPHM/WYE), which is probably dead due to liver toxicity: #msg-21978725.
JMHO, FWIW
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.